These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7903380)

  • 1. Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. The Italian Zidovudine Evaluation Group.
    Vella S; Giuliano M; Dally LG; Agresti MG; Tomino C; Floridia M; Chiesi A; Fragola V; Moroni M; Piazza M
    J Acquir Immune Defic Syndr (1988); 1994 Jan; 7(1):31-8. PubMed ID: 7903380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
    N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.
    Lancet; 1994 Apr; 343(8902):871-81. PubMed ID: 7908356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.
    Goldstein G; Conant MA; Beall G; Grossman HA; Galpin JE; Blick G; Calabrese LH; Hirsch RL; Fisher A; Stampone P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):279-88. PubMed ID: 7859140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
    JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study.
    Graham NM; Zeger SL; Park LP; Phair JP; Detels R; Vermund SH; Ho M; Saah AJ
    Lancet; 1991 Aug; 338(8762):265-9. PubMed ID: 1677108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time.
    Graham NM; Piantadosi S; Park LP; Phair JP; Rinaldo CR; Fahey JL
    J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1258-66. PubMed ID: 7901384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.
    Choi S; Lagakos SW; Schooley RT; Volberding PA
    Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
    Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction.
    Edlin BR; Weinstein RA; Whaling SM; Ou CY; Connolly PJ; Moore JL; Bitran JD
    J Infect Dis; 1992 May; 165(5):793-8. PubMed ID: 1349031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
    Hamilton JD; Hartigan PM; Simberkoff MS; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM
    N Engl J Med; 1992 Feb; 326(7):437-43. PubMed ID: 1346337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
    Ebert S; Gockel K; Horowitz S; Weber P; Vogelman B; Graziano F
    Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
    Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
    Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.
    Merigan TC; Amato DA; Balsley J; Power M; Price WA; Benoit S; Perez-Michael A; Brownstein A; Kramer AS; Brettler D
    Blood; 1991 Aug; 78(4):900-6. PubMed ID: 1831059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.
    Yarchoan R; Venzon DJ; Pluda JM; Lietzau J; Wyvill KM; Tsiatis AA; Steinberg SM; Broder S
    Ann Intern Med; 1991 Aug; 115(3):184-9. PubMed ID: 1676252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.